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Abstract
Traditionally, the dose of haemodialysis or haemofiltration delivered to patients with kidney failure is
assessed by urea clearance. For patients with chronic kidney disease below a critical urea clearance
threshold, patient wellbeing is compromised. It was suggested, therefore, that the dose of dialysis or
haemofiltration delivered could also affect outcomes for patients with acute kidney injury. Two major
prospective multicentre clinical trials have recently reported that a higher intensity of renal support,
by either intermittent haemodialysis or continuous renal replacement therapy, did not improve
patient survival or recovery from dialysis. It must be recognised, however, that urea clearance is only
one component of renal supportive therapy, and other aspects, including volume control, electrolyte
homeostasis and acid-base balance, may be equally important targets for patients with acute kidney
injury.
Introduction and context
The National Cooperative Dialysis Study, the first
randomised controlled study of dialysis dose, defined an
‘adequacy’ threshold for end-stage chronic kidney disease
patients receiving chronic haemodialysis [1] based on the
dialyser clearance of urea, a small solute marker of
nitrogen turnover, which was defined in terms of a
dimensionless parameter known as the normalised urea
clearance, or Kt/V (K, dialyzer urea clearance; t, dialysis
session duration; and V, urea volume distribution). Below
asessionalthresholdKt/Vof0.9forstandardthrice-weekly
schedules, complication-free survival was compromised
within months [2]. Subsequent observational studies
suggested that higher doses resulted in improved longer-
term outcomes [3,4], and by consensus the minimum
target Kt/V was raised to 1.2 [5]. A subsequent prospective
randomised controlled study, the Hemodialysis (HEMO)
study, reported that higher doses did not appear to further
improve outcome [6]. However, subgroup analysis
suggested that women may benefit from higher Kt/V
doses,fuellingsuggestionsthat usingstandardKt/Vtargets
to prescribe dialysis may lead to under-dosing in women
andsmallmen [7].Thesestudies suggestthat,for standard
thrice-weekly therapy, medium-term survival (measured
in months) is dependent on achieving a minimum level
of small solute removal, as defined by the National
Cooperative Dialysis Study.
Just as the amount of dialysis delivered to patients with
end-stage chronic kidney disease is important in deter-
mining survival, it was reported that the dose of
intermittent haemodialysis or continuous renal replace-
ment therapy (CRRT) was also important in determining
survival in patients with acute kidney injury (AKI) [8-10],
althoughthiswasnotauniversalfinding [11].Aspatients
with AKI continue to have high mortality, and evidence-
based clinical management is somewhat limited [12],
two prospective multicentre trials were designed to
investigatetheeffect of dose ofrenalreplacementtherapy
on outcome in patients with AKI [13,14].
Recent advances
The Veterans Affairs/National Institutes of Health
(VA/NIH) study essentially randomised patients to
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of intermittent haemodialysis, or an intensive or less
intensive dose of CRRT [13], depending upon severity of
illness at the time of randomisation. (During the course
of the study patients were switched between treatment
modalities according to haemodynamic stability.) Dur-
ing haemofiltration, it is assumed that urea is effectively
cleared (to the extent that the concentration in the
effluent ultrafiltrate is equal to that of plasma water) so
that urea clearance can simply be assessed by the total
ultrafiltration volume achieved. In this study, more
intensive renal replacement therapy did not show any
survival advantage for either the intermittent haemodia-
lysis or CRRT groups. However, the minimum haemo-
dialysis target Kt/V of 1.2 was somewhat higher than
that typically prescribed for patients with AKI by the
recruiting centres. In addition, there was no survival
advantage for the haemofiltration cohort compared to
those treated by dialysis. Haemofiltration clears solutes
primarily by convection, thus removing a larger spectrum
of solutes than haemodialysis, which predominantly
clears small water soluble solutes by diffusion.
The second study, the RENAL (Randomised Evaluation
of Normal versus Augmented Level of renal replacement
therapy in ICU) study, assessed the effect of an
augmented dose of CRRT (an ultrafiltration rate of
40 ml/kg/h versus 25 ml/kg/h) [14]. Once again, this
study failed to show any significant effect of dose of
convective renal replacement therapy on patient out-
comes, although the delivered dosages were less than
that prescribed and both small patients (<60 kg) and
very heavy patients (>120 kg) were excluded.
Implications for clinical practice
What implications do these studies have for the clinical
management of patients with AKI? Although urea can
dissociate to cyanate in plasma water and then form
carbamylated products in a reversible fashion, with some
analogy to glycosylation [15], it would appear that
toxicity from the accumulation of small nitrogenous
solutes is not the major determinant of short-term
outcome (days to weeks) in patients with AKI.
AKI frequently occurs in the setting of multiple organ
failure, and mortality remains high, with patient out-
come typically dependent upon the severity of the
underlying condition and associated co-morbidities.
The replacement of organ function may play a critical
short-term role in maintaining life in patients already
destined by other factors to have the potential to recover.
However, urea clearance is only one component of renal
replacement therapies. For example, failure to correct
persistent volume overload is associated with not only
increased post-surgical morbidity [16], but also
increased risk of AKI [17] and mortality [18]. Thus, for
patients with AKI, the adequate removal of even smaller
moieties than urea is the principal determinant of the
‘adequacy’ of renal replacement. These moieties are the
neglected ‘uraemic’ toxins, including potassium, sodium,
hydrogen ions and water [19] (Figure 1). The con-
sequences of the accumulation of these moieties,
hyperkalaemia, pulmonary oedema, and acidosis, may
be lethal in minutes [20].
Although the delivery of higher doses of haemofiltration
or more frequent haemodialysis did not improve overall
outcome, higher volume CRRT exchange cycles and more
frequent haemodialysis treatments will help correct
acidosis, and may be appropriate during the initial
resuscitation phase of AKI. Correction of volume over-
load may help explain the positive findings and
improved clinical outcomes reported from some of the
earlier trials of increased dose of renal support [9],
compared to the more recent VA/NIH and RENAL
studies, which had similar fluid balance targets.
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Figure 1. Schematic hypothetical representation of the time
course for the accumulation of azotemic toxins in patients with
both acute kidney injury and chronic kidney failure
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The schematic illustrates that different ‘toxins’ play a role over time, and as
such may require different clinical management strategies. HEMO,
Hemodialysis; NCDS, National Cooperative Dialysis Study; RENAL,
Randomised Evaluation of Normal versus Augmented Level of renal
replacement therapy in ICU; VA/NIH, Veterans Affairs/National Institutes of
Health.
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